Cutler Group LP Ngm Biopharmaceuticals Inc Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	BUY	$1.17 - $1.92 $351 - $576	300 New	300 $0
Q3 2022 Oct 25, 2022	BUY	$12.59 - $17.67 $15,108 - $21,204	1,200 Added 300.0%	1,600 $1,000
Q2 2022 Aug 04, 2022	SELL	$10.58 - $17.5 $31,740 - $52,500	-3,000 Reduced 88.24%	400 $0
Q1 2022 Apr 14, 2022	SELL	$13.81 - $18.6 $230,627 - $310,620	-16,700 Reduced 83.08%	3,400 $3,000
Q4 2021 Jan 18, 2022	BUY	$17.26 - $22.02 $291,694 - $372,138	16,900 Added 528.13%	20,100 $14,000
Q3 2021 Oct 26, 2021	BUY	$20.15 - $26.19 $52,389 - $68,094	2,600 Added 433.33%	3,200 $0
Q3 2020 Oct 27, 2020	SELL	$15.59 - $19.97 $1,559 - $1,997	-100 Reduced 14.29%	600 $0
Q2 2020 Jul 22, 2020	BUY	$11.97 - $23.47 $8,379 - $16,429	700 New	700 $2,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.